Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Where is the bottom? Sub 1 again??? just dont get it

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Apr 21, 2021 12:35pm

220 Views

Post# 33037591

RE:RE:RE:RE:RE:Where is the bottom? Sub 1 again??? just dont get it

Replying to JourneyTC,

I recall the company and Brad indicating they thought neoadjuvant treatment might be a good avenue for ONCY. But at the time they were oriented toward indications like the head and neck trail, and then a series of quick ideas Brad would come up with.

There was no real basis for any strategic planning or priority setting for the company. Brad hired his daughter, a newly minted lawyer, to the be head of strategic planning. Brad was overconfident and not systematic.

Now the situation is entirely different. We have clear scientific reasoning and abundant evidence to show how ONCY primes the immune system for immunotherapies.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market